Understand the care before you choose it.
Evidence-led treatment guides, practical comparisons and honest explanations of what is registered, compounded or still experimental.
Treatment library
Every treatment, explained plainly.
Testosterone Replacement Therapy (TRT)
Testosterone Replacement Therapy restores testosterone to the normal range in people with clinically confirmed androgen deficiency. It is a registered, well-studied medicine — but it works by switching off the body's own production, the symptom benefits in trials were more selective than the marketing suggests, and the cardiovascular safety question took a decade and a dedicated trial to settle only partly.
Read guideSemaglutide
Semaglutide is a TGA-registered, prescription-only GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. The trial evidence is unusually strong — roughly 15% average weight loss over 68 weeks, and a genuine reduction in cardiovascular events in the SELECT trial. The parts that get less airtime: most of the weight comes back when it stops, a meaningful share of what is lost is lean tissue, gastrointestinal side effects drive real discontinuation, and compounded copies sold in Australia have been a documented safety hazard.
Read guideTirzepatide
Tirzepatide is a TGA-registered, prescription-only dual GIP and GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management and obstructive sleep apnoea in adults with obesity. It produced the largest average weight loss yet seen from a medicine — around 20% in trials, and more than semaglutide head-to-head. The honest caveats: the GIP mechanism is still not fully understood, the withdrawal trial showed most of the benefit reverses when it stops, its cardiovascular outcome evidence is less mature than semaglutide's, and it interferes with oral contraception.
Read guideBPC-157
BPC-157 is a synthetic 15-amino-acid peptide with a large and reasonably consistent animal literature behind it for tendon, muscle and gut repair — and no completed large randomised trial in humans. In Australia it is not registered on the ARTG, is handled as a prescription-only compounded preparation, and is prohibited in sport at all times.
Read guideTB-500 (Thymosin Beta-4)
TB-500 is a synthetic fragment marketed as a version of thymosin beta-4, a naturally occurring protein that binds actin and regulates how cells move into damaged tissue. The parent protein has been through early human trials for specific conditions; the fragment sold as TB-500 has not been shown to work for the muscle, tendon and recovery uses it is promoted for. In Australia it is unregistered, prescription-only, and prohibited in sport at all times.
Read guideCJC-1295
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone, engineered to resist breakdown and — in the DAC form — to bind albumin so it stays active for days. Early human trials showed it raises growth hormone and IGF-1. What no trial has shown is that raising those markers produces the body-composition, recovery or anti-ageing outcomes it is marketed for. In Australia it is unregistered, prescription-only, and prohibited in sport.
Read guideIpamorelin
Ipamorelin is a synthetic pentapeptide that acts on the ghrelin receptor to trigger a pulse of growth hormone. Its distinguishing feature is selectivity — it raised GH without the cortisol and prolactin rises seen with older secretagogues. Selectivity is a pharmacological advantage, not a demonstrated clinical benefit: the uses it is promoted for have not been established in human trials. In Australia it is unregistered, prescription-only, and prohibited in sport.
Read guideNAD+ (and NMN / NR)
NAD+ is a coenzyme every cell depends on, both as an electron carrier and as a consumable substrate for sirtuins and PARPs. Levels fall with age, and precursors like NMN and NR reliably raise them in humans. What has not been shown is that raising the number changes how you age — and that gap between a biomarker and an outcome is the whole argument.
Read guideLatest thinking
Articles that separate evidence from hype.
Growth hormone peptides in Australia, explained
CJC-1295, Ipamorelin and the GH secretagogues — what they are, what the evidence actually shows, and why they belong under a doctor.
Read article Research watchThe 'research compounds' everyone's asking about: SLU-PP-332 and MOTS-c
Exercise mimetics are having a moment online. Here's a clear-eyed look at SLU-PP-332 and MOTS-c — and why 'experimental' is the operative word.
Read article WeightSemaglutide vs Tirzepatide: how Australia's GLP-1 weight medicines compare
Two TGA-registered medicines, one or two hormone pathways, and a head-to-head trial. Here's how Ozempic/Wegovy and Mounjaro stack up.
Read article